|
Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) is a specialty healthcare product company focused on developing and commercializing innovative treatments for underserved patient populations primarily in the areas of dermatologic disorders. Manhattan Pharmaceuticals (through a strategic joint venture partnership with Nordic Biotech) is currently developing Hedrin, a novel, non-pesticide treatment for pediculosis (head lice) and a topical GEL for the treatment of psoriasis.
Manhattan Pharmaceuticals is located in New York City and is traded on the OTC Bulletin Board® under the ticker symbol "MHAN".
| Copyright © Manhattan Pharmaceuticals, Inc. All Rights Reserved. Privacy Policy. |